Now showing items 1-3 of 3
| Title | Author(s) | Journal | Issue Date | Type |
|---|---|---|---|---|
| The role of raltegravir in the treatment of HIV-2 infections: evidence from a case series | Peterson, K.; Ruelle, J.; Vekemans, M.; Siegal, F. P.; Deayton, J. R.; Colebunders, R. | Antiviral Therapy | 2012 | Article |
| Novel agents for the treatment of HIV-2 infection | Peterson, K.; Rowland-Jones, S. | Antiviral Therapy | 2012 | Article |
| HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme [letter] | Florence, E.; De Wit, S.; Castagna, A.; Ribera, E.; Hill, A.; Vanaken, H.; van Delft, Y.; Marks, S. | International Journal of STD & AIDS | 2010 | Letter |
Now showing items 1-3 of 3